No #scandal here, say rare disease #drugmakers, as #pricing scrutiny lands on their doorstep

///No #scandal here, say rare disease #drugmakers, as #pricing scrutiny lands on their doorstep

No #scandal here, say rare disease #drugmakers, as #pricing scrutiny lands on their doorstep

Rare disease drugmakers, which have historically been better able to justify high prices than their peers, have recently ended up in the hot seat.

 

Gamida Cell & VBL Therapeutics to present at MIXiii Biomed.

Source: http://www.fiercepharma.com/pharma/no-scandal-here-say-rare-disease-drugmakers-as-pricing-scrutiny-lands-their-doorstep

JOIN OUR GROUP

By | 2017-05-21T07:45:43+00:00 May 21st, 2017|Blog|Comments Off on No #scandal here, say rare disease #drugmakers, as #pricing scrutiny lands on their doorstep

About the Author: